DiscoverBioBiz Buzz
BioBiz Buzz
Claim Ownership

BioBiz Buzz

Author: https://biobizbuzz.com/

Subscribed: 1Played: 17
Share

Description

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. 


Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. 


 

Disclaimer

https://biobizbuzz.com/disclaimer/

29 Episodes
Reverse
What transforms a promising scientific opportunity into a viable biotechnology company? In this episode of BioBiz Buzz, Mike Ward speaks with Dr Jonathan Talbot, CEO of Melodia Therapeutics, co-founder and former CEO of Mosanna Therapeutics, and winner of the 2026 Strüngmann Award. The award recognises life-sciences entrepreneurs who combine scientific insight with the strategic and operational ability to translate innovation into successful products and companies. Jonathan Talbot expla...
In this episode of BioBiz Buzz, your host Mike Ward explores a critical, but often underappreciated, driver of vision loss in retinal diseases; the breakdown of the blood–retina barrier (BRB). While anti-VEGF therapies have transformed outcomes in diabetic macular oedema (DME) and wet age-related macular degeneration (AMD), many patients continue to experience incomplete responses, recurrence, and progressive vision loss; highlighting the limitations of therapies that primarily target downstr...
In this episode of BioBiz Buzz, Mike Ward talks to Dr Sam Possemiers, founder and CEO of Belgium-based MRM Health, about what it really takes to turn the human gut microbiome into a bona fide drug modality. They trace the arc from crude faecal microbiota transplants and limited single-strain probiotics to rationally designed consortia of commensal bacteria that function as a single, scalable therapeutic product. Moreover, Possemiers explains how MRM Health’s Coral platform starts with p...
Targeted protein degradation has moved from elegant academic concept to one of the most closely watched frontiers in oncology, promising to drug the 80% of disease‑driving proteins that traditional inhibitors and even ADCs still struggle to reach. In this episode of BioBiz Buzz, host Mike Ward sits down with Proxygen founder and scientific advisor Georg Winter and CSO Chiara Conti to unpack how induced proximity, molecular glue degraders and ligase choice are reshaping the precision oncology ...
For years, the narrative was simple: if you wanted a multibillion-dollar biotech outcome, you built in Boston or the Bay Area. Gilead’s up to $5 billion acquisition of Munich-based Tubulis just blew that up. In this episode, Mike Ward and Andera Partners’ Sofia Ioannidou go inside one of Europe’s most important biotech exits to unpack what really drove the deal, and why it wasn’t just about a single ADC asset, but a platform Gilead believes can keep delivering. They dig into the mechani...
loading
Comments